Wei‐Xing Guo

机构：Second Military Medical University, Eastern Hepatobiliary Surgery Hospital

发表论文 147 篇 · 总被引 4620 次 · h-index 33

代表论文

• Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial (2024 · Nature Medicine · 被引 130)
• Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study (2023 · Signal Transduction and Targeted Therapy · 被引 28)
• Short-term and long-term outcomes after robotic versus open hepatectomy in patients with large hepatocellular carcinoma: a multicenter study (2023 · International Journal of Surgery · 被引 21)
• Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors (2023 · BMC Cancer · 被引 17)
• Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial (2025 · Signal Transduction and Targeted Therapy · 被引 14)
• MicroRNA‑21: A potential therapeutic target in lung cancer (Review) (2025 · International Journal of Oncology · 被引 13)